Italfarmaco To Seek Givinostat Approvals After Phase III Success In DMD
Capricor Reported Long-Term Data For Its Cell Therapy
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.
